This small-cap pharma stock engaged in providing integrated solutions in pharmaceutical, biotechnology, and specialty chemicals, offering services such as drug development and manufacturing, jumped 10 percent after receiving a Drug Manufacturing License from the National Medical Product Administration (NMPA) for its Shanghai site in China.
Stock Price Movement:
With a market capitalization of Rs. 3,180.35 crores, the share of Dishman Carbogen Amcis Limited has reached an intraday high of Rs. 207 per equity share, rising nearly 10.4 percent from its previous day’s close price of Rs. 187.50. Since then, the stock has retreated and is currently trading at Rs. 202.85 per equity share.
What Happened:
Dishman Carbogen Amcis Limited is pleased to announce that its wholly-owned subsidiary, CARBOGEN AMCIS (Shanghai) Co. Ltd., has received a Drug Manufacturing License from the National Medical Product Administration (NMPA) for its Shanghai site in China. This approval will allow the subsidiary to commence drug manufacturing at its Shanghai location.
Management Guidance:
The company aims to reduce its net debt to below CHF 120 million within the next three years, targeting a net leverage ratio of 1.5 to 2. It expects revenue growth of around 10 percent annually over the next 3-5 years, driven by the integration of Dishman and Carbogen Amcis. Additionally, the company anticipates improving EBITDA margins to 20 percent in the next fiscal year, with a long-term goal of reaching 24-25 percent by FY28.
Future Outlook:
The company’s management is hopeful about the next year, expecting the French subsidiary to break even and strong revenue growth from ADC and bioconjugation projects. The company aims to take advantage of new opportunities in the pharmaceutical industry, especially the rising demand for ADCs and peptide drug conjugates.
Recent quarter results:
Dishman Carbogen Amcis Limited’s revenue has increased from Rs. 651.09 crore in Q3 FY24 to Rs. 682.34 crore in Q3 FY25, which has grown by 4.80 percent. The net loss has converted into net profit, from Rs. -59.63 crore in Q3 FY24 to Rs. 4.63 crore in Q3 FY25.
Written By – Nikhil Naik
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
